EVO ICL

Name

EVO ICL

Legal name

STAAR Surgical Company

Website

https://us.discovericl.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

akta.pro secondary industry

Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment) (HLAHAJAD)

Keywords

• Implantable collamer lens
• Refractive lens implant
• Vision correction surgery
• Ophthalmic medical devices
• Myopia treatment

Headquarters

HQ city

Lake Forest

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales

Revenue model

1. Implantable Lens Sales: One-time sale of the EVO ICL implantable lens to eye care professionals and clinics. The procedure cost varies by prescription, location, and provider, with most clinics offering payment plans. The company also offers financing options through CareCredit.
2. Procedure Financing: The company facilitates financing through CareCredit, allowing patients to pay as low as $10 per day / $300 per month (approximately 24 months). FSA and HSA accounts are also accepted as qualified expenses.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

EVO ICL manufactures and markets the EVO Visian ICL, an implantable Collamer lens that corrects moderate to high nearsightedness (-3D to -20D) and astigmatism (1D to 4D). The lens is implanted between the iris and the natural crystalline lens in a 20–30 minute outpatient procedure by certified ophthalmologists. STAAR Surgical Company (NASDAQ: STAA) is the legal manufacturer and parent entity behind the EVO ICL brand.

Product overview

EVO ICL is a family of implantable collamer lenses for vision correction, manufactured by STAAR Surgical. The core product line consists of the EVO ICL (spherical) and EVO TICL (toric for astigmatism) lenses, both made from the proprietary Collamer material. These lenses correct nearsightedness from -3D to -20D and astigmatism from 1.0D to 4.0D through an additive, minimally invasive 20-30 minute procedure. The lenses are implanted between the iris and natural crystalline lens, are reversible, and do not remove corneal tissue. The product received FDA approval and over 4 million ICL lenses have been distributed worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• EVO Visian ICL Lens (EVO ICL and EVO TICL) An FDA-approved implantable Collamer lens that corrects moderate to high nearsightedness (-3D to -20D) with and without astigmatism (1D to 4D). Implanted between the iris and natural crystalline lens through a small incision in a 20-30 minute outpatient procedure. Reversible, does not remove corneal tissue, and does not cause dry eye syndrome. Sold to certified ophthalmologists and optometrists who perform the implantation procedure.

Quantifiable outcome

• 99.4% patient satisfaction - would have the EVO procedure again
• +3 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Alcon: Alcon is the largest eye-care device company globally, offering cataract IOLs, refractive surgery platforms, and contact lens care products. While Alcon does not sell a phakic IOL equivalent to EVO ICL, it directly competes in surgical vision correction and dominates the ophthalmic surgeon channel used by STAAR.
• EssilorLuxottica: EssilorLuxottica is the dominant ophthalmic lens and eyewear manufacturer, competing indirectly with EVO ICL by capturing patients who stay in glasses/contact lenses rather than seeking surgical correction.
• Johnson & Johnson Vision (TECNIS, AcuFocus): J&J Vision offers TECNIS IOLs and acquired AcuFocus (ICL-adjacent small-aperture lens technology), making it a broad incumbent competing with EVO ICL across premium cataract and refractive surgery.
• Bausch + Lomb (BVI): Bausch + Lomb / BVI manufactures intraocular lenses and ophthalmic surgical devices, directly competing with STAAR in the IOL category and sharing the same surgeon-distribution ecosystem.

Direct peers

• NIDEK: NIDEK manufactures ophthalmic diagnostic and refractive surgery equipment including excimer lasers and IOLs, competing directly with STAAR for surgical vision-correction procedures.
• Carl Zeiss Meditec: Carl Zeiss Meditec is the leading refractive surgery laser platform provider (including SMILE/SMILE Pro), directly competing with EVO ICL for the surgical myopia correction dollar and sharing ophthalmology customer relationships.
• Rayner Intraocular Lenses: Rayner manufactures a broad portfolio of IOLs including monofocal, toric, and multifocal lenses, making it a direct competitor for ophthalmic surgical lens share versus STAAR's EVO ICL.
• HOYA Surgical Optics: HOYA is a major IOL manufacturer offering preloaded and toric intraocular lenses, directly competing with STAAR's EVO ICL franchise for surgeon share in ophthalmic surgery centers.

Regional players

• CooperVision (CooperCompanies): CooperVision is a leading contact lens manufacturer positioned as a primary alternative to EVO ICL for myopia correction, particularly strong in the Americas and Europe contact lens channels.

Emerging players

• Lensar (now part of Booking Holdings era predecessor / ALCON SMILE robotics adjacent): Lensar develops laser cataract surgery systems, an emerging technology competing with both IOL implantation and refractive surgery alternatives to STAAR's EVO ICL.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EVO ICL